Skip to main content

Table 2 Adverse drug reactions in the safety analysis set

From: Safety and efficacy of long-term combination therapy with bezafibrate and ezetimibe in patients with dyslipidemia in the prospective, observational J-COMPATIBLE study

Adverse drug reactions n %
Patients evaluated 659
Patients with ADRs 42 6.4
ADRs in ≥ 0.3% of patients   
 Blood CPK increased 10 1.5
 Myalgia 5 0.8
 Gallstone 4 0.6
 Blood creatinine increased 4 0.6
 AST increased 3 0.5
 Gastric cancer 2 0.3
 Diabetes 2 0.3
 Renal dysfunction 2 0.3
 ALT increased 2 0.3
 Blood TG increased 2 0.3
  1. ADRs: adverse drug reactions; CPK: creatine phosphokinase; AST: aspartate aminotransferase; ALT: alanine aminotransferase; TG: triglyceride.